Supplementary Materials

The PDF file includes:

  • Materials and Methods
  • Fig. S1. Cross-reactivity test of murine TNFR2 antibodies to other TNF superfamily receptors.
  • Fig. S2. Enhanced proliferation and activation of T cells mediated by higher-order TNFR2 cross-linking for Y9 costimulation in vitro.
  • Fig. S3. In vitro Treg suppression assay.
  • Fig. S4. In vivo activity of Y9 and anti–PD-L1 combination.
  • Fig. S5. Ligand blocking of Y9-DANA.
  • Fig. S6. Impact of treatment with Y9 on different immune cell subsets.
  • Fig. S7. Ex vivo analysis of tumor-specific CD8+ T cell responses.
  • Fig. S8. Impact of treatment with Y9 on frequency changes in the T cell compartment.
  • Fig. S9. Characterization of the tumor-associated myeloid compartment after anti-TNFR2 treatment.
  • Fig. S10. Additional data for toxicity profile of long-term exposure to anti-TNFR2 or anti–CTLA-4 antibodies in BALB/c and C57BL/6 mice.
  • Fig. S11. Serum cytokine data for toxicity profile of long-term exposure to anti-TNFR2 or anti–CTLA-4 antibodies in BALB/c and C57BL/6 mice and toxicity study in EMT6 tumor-bearing mice.
  • Fig. S12. Repeat toxicity study with anti–PD-1 combinations.
  • Fig. S13. TNFR2 receptor constructs used for epitope mapping and binding studies.
  • Fig. S14. High-resolution epitope mapping of human and mouse anti-TNFR2 antibodies.
  • Fig. S15. Gating strategy of mouse T cells in the tdLN and tumor.
  • Table S1. Description of chimeric TNFR2 constructs.
  • Table S2. Sequences of murine TNFR2 antibodies.
  • Table S3. Murine T cell flow cytometry antibodies.
  • Table S4. Human T cell flow cytometry antibodies.
  • References (52, 53)

[Download PDF]

Other Supplementary Material for this manuscript includes the following: